Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP5 | P51878 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107802 | 0.86 | CASP1 (0.41) | CASP1CASP4CASP5CHRM4CD274 | |
| SCHEMBL13098873 | 0.82 | KDM4E (0.44) | CD274 | |
| SCHEMBL13098944 | 0.81 | HRH3 (0.43) | CHKADRD2DRD4MELKSLC6A7 | |
| SCHEMBL13098927 | 0.81 | GPR119 (0.44) | CHKADRD2DRD4MELK | |
| SCHEMBL13098940 | 0.78 | DRD2 (0.46) | DRD2DRD4CHRM4MELK | |
| SCHEMBL6241221 | 0.78 | USP2 (0.46) | CHKABDKRB1CHRM4 | |
| SCHEMBL6132282 | 0.77 | PDE4D (0.46) | CHKACHRM4 | |
| SCHEMBL13098776 | 0.77 | OPRD1 (0.47) | CASP1SLC6A7 | |
| SCHEMBL6234622 | 0.76 | HDAC3 (0.57) | CHRM4 | |
| SCHEMBL3091650 | 0.76 | KDM4E (0.36) | BDKRB1CASP1CASP4CASP5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204379-A1 | POLYPEPTIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-07-07 | — | — | EP | disclosed |
| EP-2204379-A1 | POLYPEPTIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | CHKA 2702/4885DRD2 2677/4885DRD4 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.